Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ILOTYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ILOTYCIN.
AZASITE vs ILOTYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking peptidyl transferase activity and preventing translocation of peptides.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
Erythromycin base (Ilotycin): 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day. For IV: 15-20 mg/kg/day continuous infusion or divided every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life is 1.5-2 hours in adults, prolonged to 4-6 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-15% biliary/fecal elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic